Scailyte Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
Scailyte General Information
Description
Developer of an artificial intelligence biomarker discovery and sequencing analytical platform designed for the discovery of complex disease patterns from single-cell data and multi-omics data. The company's platform offers an end-to-end pipeline for the analysis of extracting relevant biosignatures from single-cell and multi-omics data related to efficacy, toxicity, or the mode of action of therapeutics, enabling physicians to reduce data analysis time and costs while increasing groundbreaking insights for patient stratification.
Contact Information
Website
www.scailyte.comCorporate Office
- Lichtstrasse 35
- WSJ-500
- 4056 Basel
- Switzerland
Corporate Office
- Lichtstrasse 35
- WSJ-500
- 4056 Basel
- Switzerland
Scailyte Timeline
Scailyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 11. Later Stage VC | 30-Jan-2024 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 23-Nov-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series A) | 12-Aug-2023 | Completed | Generating Revenue | |||
| 8. Early Stage VC | 10-Jun-2020 | Completed | Generating Revenue | |||
| 7. Early Stage VC | 19-Dec-2018 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 31-Oct-2018 | Completed | Generating Revenue | |||
| 5. Grant | 25-May-2018 | Completed | Generating Revenue | |||
| 4. Seed Round | 31-Jul-2017 | $257K | Completed | Startup | ||
| 3. Grant | 20-Jun-2017 | $10.3K | $257K | Completed | Startup |
Scailyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 6,809,484 | $0.011152 | $0.43 | $0.43 | 1x | $0.43 | 10.53% | |
| Ordinary | 526,316 | $0.011152 | $0.21 | $0.21 | 1x | $0.21 | 0.81% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Scailyte Comparisons
Industry
Financing
Details
Scailyte Competitors (34)
One of Scailyte’s 34 competitors is Aitia, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aitia | Venture Capital-Backed | Cambridge, MA | ||||
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| Strand (Biotechnology) | Formerly VC-backed | Bangalore, India | ||||
| Genuity Science | Formerly VC-backed | Dublin, Ireland | ||||
| Encellin | Venture Capital-Backed | Pleasanton, CA |
Scailyte Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Scailyte Patents
Scailyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024223379-A1 | Biomarkers for the diagnosis of diseases or disorders of the female reproductive tract | Inactive | 27-Apr-2023 | ||
| WO-2024088538-A1 | Biomarkers for the diagnosis of diseases or disorders of the female reproductive tract | Inactive | 26-Oct-2022 | ||
| WO-2023073075-A1 | Biomarker for immune checkpoint inhibitor sensitive cancer | Inactive | 26-Oct-2021 | ||
| CA-3235092-A1 | Jup biomarker for the diagnosis of diseases or disorders of the female reproductive tract | Pending | 26-Oct-2021 | ||
| WO-2023073074-A1 | Jup biomarker for the diagnosis of diseases or disorders of the female reproductive tract | Inactive | 26-Oct-2021 | G01N33/689 |
Scailyte Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Scailyte Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hera Biotech | VC-Backed Company | Minority | ||
| Plug and Play | Accelerator/Incubator | Minority | ||
| 4FOX Ventures | Venture Capital | Minority | ||
| Verve Ventures | Venture Capital | Minority | ||
| Hemex (Healthcare Services) | VC-Backed Company | Minority |
Scailyte FAQs
-
When was Scailyte founded?
Scailyte was founded in 2017.
-
Where is Scailyte headquartered?
Scailyte is headquartered in Basel, Switzerland.
-
What is the size of Scailyte?
Scailyte has 16 total employees.
-
What industry is Scailyte in?
Scailyte’s primary industry is Drug Discovery.
-
Is Scailyte a private or public company?
Scailyte is a Private company.
-
What is Scailyte’s current revenue?
The current revenue for Scailyte is .
-
How much funding has Scailyte raised over time?
Scailyte has raised $32.3M.
-
Who are Scailyte’s investors?
Hera Biotech, Plug and Play, 4FOX Ventures, Verve Ventures, and Hemex (Healthcare Services) are 5 of 9 investors who have invested in Scailyte.
-
Who are Scailyte’s competitors?
Aitia, Personalis, Strand (Biotechnology), Genuity Science, and Encellin are some of the 34 competitors of Scailyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
